These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 33799647)

  • 41. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
    Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
    Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
    Kishnani PS; Beckemeyer AA; Mendelsohn NJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Variability in the clinical presentation of Pompe disease in infancy: two case reports and response to treatment with human recombinant enzyme].
    Moreno-Medinilla E; Berzosa-López R; Mora-Ramírez MD; Blasco-Alonso J; Martínez-Antón J
    Rev Neurol; 2014 Dec; 59(11):503-7. PubMed ID: 25418145
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.
    Koeberl DD; Austin S; Case LE; Smith EC; Buckley AF; Young SP; Bali D; Kishnani PS
    FASEB J; 2014 May; 28(5):2171-6. PubMed ID: 24443373
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy.
    Terzis G; Krase A; Papadimas G; Papadopoulos C; Kavouras SA; Manta P
    Mol Genet Metab; 2012 Dec; 107(4):669-73. PubMed ID: 23146291
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
    Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
    Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined aerobic exercise and enzyme replacement therapy rejuvenates the mitochondrial-lysosomal axis and alleviates autophagic blockage in Pompe disease.
    Nilsson MI; MacNeil LG; Kitaoka Y; Suri R; Young SP; Kaczor JJ; Nates NJ; Ansari MU; Wong T; Ahktar M; Brandt L; Hettinga BP; Tarnopolsky MA
    Free Radic Biol Med; 2015 Oct; 87():98-112. PubMed ID: 26001726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
    Byrne BJ; Geberhiwot T; Barshop BA; Barohn R; Hughes D; Bratkovic D; Desnuelle C; Laforet P; Mengel E; Roberts M; Haroldsen P; Reilley K; Jayaram K; Yang K; Walsh L;
    Orphanet J Rare Dis; 2017 Aug; 12(1):144. PubMed ID: 28838325
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improvement of bone mineral density after enzyme replacement therapy in Chinese late-onset Pompe disease patients.
    Sheng B; Chu YP; Wong WT; Yau EKC; Chen SPL; Luk WH
    BMC Res Notes; 2017 Jul; 10(1):351. PubMed ID: 28754168
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of interrupting enzyme replacement therapy in late-onset Pompe disease.
    Wenninger S; Gutschmidt K; Wirner C; Einvag K; Montagnese F; Schoser B
    J Neurol; 2021 Aug; 268(8):2943-2950. PubMed ID: 33625582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
    Masat E; Laforêt P; De Antonio M; Corre G; Perniconi B; Taouagh N; Mariampillai K; Amelin D; Mauhin W; Hogrel JY; Caillaud C; Ronzitti G; Puzzo F; Kuranda K; Colella P; Mallone R; Benveniste O; Mingozzi F;
    Sci Rep; 2016 Nov; 6():36182. PubMed ID: 27812025
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nutritional co-therapy with 1,3-butanediol and multi-ingredient antioxidants enhances autophagic clearance in Pompe disease.
    Nilsson MI; Crozier M; Di Carlo A; Xhuti D; Manta K; Roik LJ; Bujak AL; Nederveen JP; Tarnopolsky MG; Hettinga B; Meena NK; Raben N; Tarnopolsky MA
    Mol Genet Metab; 2022; 137(1-2):228-240. PubMed ID: 35718712
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease.
    Raben N; Schreiner C; Baum R; Takikita S; Xu S; Xie T; Myerowitz R; Komatsu M; Van der Meulen JH; Nagaraju K; Ralston E; Plotz PH
    Autophagy; 2010 Nov; 6(8):1078-89. PubMed ID: 20861693
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
    Kobayashi H; Shimada Y; Ikegami M; Kawai T; Sakurai K; Urashima T; Ijima M; Fujiwara M; Kaneshiro E; Ohashi T; Eto Y; Ishigaki K; Osawa M; Kyosen SO; Ida H
    Mol Genet Metab; 2010 May; 100(1):14-9. PubMed ID: 20202878
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT.
    Fernández-Simón E; Carrasco-Rozas A; Gallardo E; González-Quereda L; Alonso-Pérez J; Belmonte I; Pedrosa-Hernández I; Montiel E; Segovia S; Suárez-Calvet X; Llauger J; Mayos M; Illa I; Barba-Romero MA; Barcena J; Paradas C; Carzorla MR; Creus C; Coll-Cantí J; Díaz M; Domínguez C; Fernández-Torrón R; García-Antelo MJ; Grau JM; López de Munáin A; Martínez-García FA; Morgado Y; Moreno A; Morís G; Muñoz-Blanco MA; Nascimento A; Parajuá-Pozo JL; Querol L; Rojas R; Robledo-Strauss A; Rojas-Marcos Í; Salazar JA; Usón M; Díaz-Manera J
    Mol Genet Metab; 2019; 128(1-2):129-136. PubMed ID: 31378569
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry.
    Martinez-Marin RJ; Reyes-Leiva D; Nascimento A; Muelas N; Dominguez-González C; Paradas C; Olivé M; García-Romero M; Pascual-Pascual SI; Grau JM; Barba-Romero MA; Gomez-Caravaca MT; de Las Heras J; Casquero P; Mendoza MD; de León JC; Gutierrez A; Morís G; Blanco-Lago R; Ramos-Fransi A; Pintós G; García-Antelo MJ; Rabasa M; Morgado Y; Usón M; Miralles FJ; Bárcena-Llona JE; Gómez-Belda AB; Pedraza-Hueso MI; Hortelano M; Colomé A; Garcia-Martin G; Lopez de Munain A; Jericó I; Galán-Dávila L; Pardo J; Salgueiro-Origlia G; Alonso-Pérez J; Pla-Junca F; Schiava M; Segovia-Simón S; Díaz-Manera J
    Neuromuscul Disord; 2024 Jan; 34():1-8. PubMed ID: 38087756
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Satellite cells fail to contribute to muscle repair but are functional in Pompe disease (glycogenosis type II).
    Lagalice L; Pichon J; Gougeon E; Soussi S; Deniaud J; Ledevin M; Maurier V; Leroux I; Durand S; Ciron C; Franzoso F; Dubreil L; Larcher T; Rouger K; Colle MA
    Acta Neuropathol Commun; 2018 Oct; 6(1):116. PubMed ID: 30382921
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Body composition and 6 minute walking ability in late-onset pompe disease patients after 9 years of enzyme replacement therapy.
    Terzis G; Papadimas G; Krase A; Kontou E; Arnaoutis I; Papadopoulos C
    Int J Neurosci; 2022 Jul; 132(7):699-705. PubMed ID: 33045893
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease.
    Hintze S; Limmer S; Dabrowska-Schlepp P; Berg B; Krieghoff N; Busch A; Schaaf A; Meinke P; Schoser B
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.